Project description:BackgroundTumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying exceptional responders retrospectively, obtaining pre-exceptional response treatment tumor tissues, and analyzing them with state-of-the-art molecular analysis tools to identify potential molecular explanations for responses.MethodsExceptional response was defined as partial (PR) or complete (CR) response to a systemic treatment with population PR or CR rate less than 10% or an unusually long response (eg, duration >3 times published median). Cases proposed by patients' clinicians were reviewed by clinical and translational experts. Tumor and normal tissue (if possible) were profiled with whole exome sequencing and, if possible, targeted deep sequencing, RNA sequencing, methylation arrays, and immunohistochemistry. Potential germline mutations were tracked for relevance to disease.ResultsCases reflected a variety of tumors and standard and investigational treatments. Of 520 cases, 476 (91.5%) were accepted for further review, and 222 of 476 (46.6%) proposed cases met requirements as exceptional responders. Clinical data were obtained from 168 of 222 cases (75.7%). Tumor was provided from 130 of 168 cases (77.4%). Of 117 of the 130 (90.0%) cases with sufficient nucleic acids, 109 (93.2%) were successfully analyzed; 6 patients had potentially actionable germline mutations.ConclusionExceptional responses occur with standard and investigational treatment. Retrospective identification of exceptional responders, accessioning, and sequencing of pretreatment archived tissue is feasible. Data from molecular analyses of tumors, particularly when combining results from patients who received similar treatments, may elucidate molecular bases for exceptional responses.

| S-EPMC7781457 | biostudies-literature

A223 bintrafusp alfa non-responders and responders

Project description:A223 bintrafusp alfa non-responders and responders

| PRJNA677973 | ENA

Tear proteome of patients with non-infectious uveitis responders and non-responders to adalimumab

Project description:Proteomic anaysis of tear samples from patients with non-infectious uveitis responders and non-responders to adalimumab included in a cross-sectional study

| MSV000095892 | MassIVE

Childhood Cancer Data Initiative (CCDI): NCI CCSG CCDI Supplement Additional Genomic Submission (Funded to OHSU)

Project description:Childhood Cancer Data Initiative (CCDI): NCI CCSG CCDI Supplement Additional Genomic Submission (Funded to OHSU)

| PRJNA761481 | ENA

Childhood Cancer Data Initiative (CCDI): NCI CCSG CCDI Supplement Additional Genomic Submission (Funded to OHSU)

Project description:Childhood Cancer Data Initiative (CCDI): NCI CCSG CCDI Supplement Additional Genomic Submission (Funded to OHSU)

| PRJNA761482 | ENA

i5k initiative

Project description:i5k initiative

| PRJNA163993 | ENA

NCI-H460-LNM35 vs NCI-H460-N15

Project description:Comparing genome-wide gene expression profiles of highly metastatic lung cancer cell line NCI-H460-LNM35 vs low metastatic parental clone NCI-H460-N15 Keywords: Expression profiling with cDNA microarray

2010-08-21 | GSE16649 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data